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Resistant hypertension is deﬁned as blood pressure above the patient’s goal despite the use of 3 or more antihypertensive
agents from diﬀerent classes at optimal doses, one of which should ideally be a diuretic. Evaluation of patients with resistive
hypertension should ﬁrst conﬁrm that they have true resistant hypertension by ruling out or correcting factors associated
with pseudoresistance such as white coat hypertension, suboptimal blood pressure measurement technique, poor adherence to
prescribed medication, suboptimal dosing of antihypertensive agents or inappropriate combinations, the white coat eﬀect, and
clinical inertia. Management includes lifestyle and dietary modiﬁcation, elimination of medications contributing to resistance,
andevaluationofpotentialsecondarycauses ofhypertension. Pharmacologicaltreatment shouldbe tailored to thepatient’s proﬁle
andfocus on the causative pathwayof resistance. Patients with uncontrolled hypertension despite receiving an optimaltherapy are
candidates for newer interventional therapies such as carotid baroreceptor stimulation and renal denervation.
1.Introduction
Hypertension is the most common chronic disease in the
developed world aﬀecting up to 25% of the adult population
[1]. It remains the most important modiﬁable risk factor for
coronary heart disease, stroke, congestive heart failure, renal
disease, and peripheral vascular disease. Suboptimal blood
pressure control is responsible for 62% of cerebrovascular
disease, 49% of ischemic heart disease, and an estimated
7.1 million deaths a year [2]. Because of the associated
morbidity, mortality and economic cost to society early
diagnosis and treatment within the established guidelines
is imperative. A sizeable percentage of the hypertensive
population does not manage to achieve adequate control in
spite of receiving 3 or more antihypertensive medications.
These are the patients with resistant hypertension.
Resistant hypertension is deﬁned by the Joint National
Committee7asbloodpressurethatisabovethepatient’sgoal
despite the use of 3 or more antihypertensive agents from
diﬀerentclassesat optimaldoses, oneofwhich should ideally
be a diuretic [3]. Patients whose blood pressure is controlled
but require 4 or more medications to do so should also be
considered resistant to treatment. However, the deﬁnition
does not include newly diagnosed hypertensives. Resistant
hypertension is not synonymous with uncontrolled hyper-
tension. The latter includes both patients with inadequately
treated blood pressure due to poor adherence or inadequate
treatment, as well as those with true resistant hypertension
[3, 4]. The importance of resistant hypertension lies in the
identiﬁcation of patients who are at high risk of suﬀering
complications from reversible causes of hypertension and
patients who may beneﬁt from a particular diagnostic or
therapeutic approach [3].
The exact prevalence of resistant hypertension is un-
known, in part because of its arbitrary deﬁnition. However,
small studiesestimateprevalencefrom5%ingeneralmedical
practice upto 50%in nephrology clinics[5].In aprospective
analysis of Framingham study data, a higher baseline systolic
bloodpressure alongwitholderage,thepresenceofLVHand
obesity (BMI > 30kg/m2) were the strongest predictors of
lack of blood pressure control [6, 7]. Results were similar
in ALLHAT where the older, obese patients with higher
baseline systolic blood pressure and LVH required 2 or
more antihypertensive agents [8]. The strongest predictor2 International Journal of Hypertension
however was serum creatinine over 1.5mg/dL. Other patient
characteristics associated with resistant hypertension include
excessive salt ingestion, diabetes, black race, and female
gender. Both studies showed greater diﬃculty in controlling
systolic blood pressure compared to diastolic. Up to 92% of
patients achieved target diastolic blood pressure while only
60%–67% achieved systolic blood pressure goals [6, 8]. It is
likely that this condition will become increasingly common
because of the aging population and a progressive increase in
obesity and comorbidities such as diabetes.
There are also a few studies implicating gene mutations.
A Finnish study found that certain variants of the β and
γ subunits of the epithelial sodium channel gene ENaC
were signiﬁcantly more prevalent in patients with resistant
hypertension [9]. Other studies associate the allele of the
CYP3A5∗1 enzyme with both higher blood pressure levelsin
normotensive people of black race, as well as with hyperten-
sion resistant to treatment [10, 11]. This particular enzyme
is involved in the metabolism of cortisol and corticosterone.
These and other genes that may be identiﬁed in the future
hold the potential for the development of novel therapeutic
targets.
2.PseudoresistanceEvaluation
The workup of patients with suspected resistant hyperten-
sion is summed up in Table 3.
The ﬁrst step in evaluating a patient with uncontrolled
blood pressure is to establish whether it is a case of true
resistant hypertension or just pseudoresistance. The latter
refers to a lack of blood pressure control despite receiving
treatment without true resistance. This can be caused by
easily reversible causes such as suboptimal blood pres-
sure measurement technique, poor adherence to prescribed
medication, suboptimal dosing of antihypertensive agents
or inappropriate combinations, the white coat eﬀect, and
clinical inertia. It is important to exclude these causes before
labeling a patient as having resistant hypertension.
Poor blood pressure measurement technique is quite
common, usually the result of not letting the patient rest
before measurement and using a small cuﬀ [12]. Patients
should always rest in a chair with their back supported for a
minimum 5 minutes prior to measurement and the cuﬀ’s air
bladder must encircle at least 80% of the arm circumference.
The average of two readings taken a minute apart represents
the patient’s blood pressure.
Approximately 40% of newly diagnosed patients will
discontinue their antihypertensive medication the ﬁrst year
oftreatment [13, 14]. Eventually,less than 40% will continue
taking their medication after 5 to 10 years [13, 15]. The most
common causes are poor patient-physician communication
concerning blood pressure goals and the importance of
achieving them, potential side eﬀects, high cost of treatment,
and complex regimens [16, 17]. Adherence can be improved
by choosing aﬀordable agents with minimal side eﬀects that
are given once daily alone or in ﬁxed dose combinations.
Olderpatientswithmemory deﬁcitsorpsychiatric illnesscan
beneﬁt from using pill boxes.
Clinical inertia can be described as a physician’s igno-
rance oftreatment guidelinesorreluctancetoadheretothem
due to lack of training or inexperience in antihypertensive
medication, underestimation of cardiovascular risk, and
overestimation of the treatment provided [18, 19]. This
results in suboptimal dosing or inappropriate combinations
of agents. A large part of this problem could be resolved if
physicians familiarize themselves with one or two drugs in
each class of antihypertensives. Proper training is imperative
so that physicians realize the importance of treating to reach
a goal blood pressure level of less than 140/90mmHg and
knowing when to refer patients to a hypertension specialist.
Aw h i t ec o a te ﬀect should be suspected in patients whose
clinical blood pressure measurements are consistently and
signiﬁcantly higher than reliable out of oﬃce measurements.
Other signs include repetitive symptoms of overtreatment
such as orthostatic hypotension and persistent fatigue as
well as absence of target organ damage including left
ventricular hypertrophy, retinopathy, and chronic kidney
disease [20, 21]. These cases must be conﬁrmed with 24-
hour ambulatory blood pressure monitoring. One study
found that 20 to 30% of a patient population believed to
haveresistanthypertensionwasactuallywellcontrolledwhen
measuredby24-hourambulatorybloodpressuremonitoring
[22]. Accurate home blood pressure values are the best
guide for therapy. In elderly patients, especially diabetics,
arterial stiﬀness may cause pseudoresistance because less
compressible arteries cause falsely elevated blood pressure
[23].
3.ConcomitantConditions
As was previously mentioned, obesity is associated with
resistant hypertension. Obese patients have increased sym-
pathetic activity, higher cardiac output, and a rise in
peripheral vascular resistance due to reduced endothelium-
dependent vasodilation. Plasma aldosterone and endothelin
are also increased, while excessivesurrounding adiposetissue
results in increased intrarenal pressures and changes in
renal architecture [24]. As the body mass index increases,
progressively higher doses of antihypertensive drugs are
required to control blood pressure [25]. Weight loss has been
found to reduce both systolic and diastolic blood pressure
[3, 26].
A n o t h e rc o m m o nc o n c o m i t a n tc o n d i t i o ni nh y p e r t e n -
sive patients is diabetes. Insulin resistance increases sym-
pathetic nervous activity, vascular smooth muscle cell pro-
liferation, and sodium retention leading to elevated blood
pressure resistant to treatment [3]. The common comor-
bidities of obesity, hypertension, and diabetes induce renal
dysfunction, further hindering blood pressure treatment.
Dietary factors include increased salt and alcohol con-
sumption.Althoughsmall amountsofalcohol(2drinks/day)
have vasodilating eﬀects and may lower blood pressure, con-
sumptionofmorethan30mLdailyraisesbloodpressureand
may increase cardiovascular risk. Older patients, patients of
African origin, and patients with chronic kidney disease are
particularly susceptible to salt intake [3]. Current guidelinesInternational Journal of Hypertension 3
recommend that dietary sodium for a hypertensive person
should be under 100mmol/day (2.4g sodium or 6g sodium
chloride) and even lower in salt sensitive patients [27].
Excessive salt intake can be assessed by measuring sodium
excretion in a 24-hour urine collection.
Several common medications can cause elevated blood
pressure and hinder treatment. Perhaps the most com-
mon are nonsteroidal anti-inﬂammatories including COX-
2 inhibitors and aspirin, decongestants (phenylephrine
and pseudoephedrine), stimulant agents used for weight
loss, narcolepsy or attention deﬁcit disorder, contracep-
tives, cyclosporine, and erythropoietin [3]. Corticosteroids
increase blood pressure through ﬂuid retention, particularly
but not limited to those with increased mineralocorticoid
activity. Licorice and herbal medication that contains stim-
ulants such as ephedra can also cause hypertension.
4.Assessment ofSecondaryCausesof
Hypertension
Secondary causes of hypertension are common in patients
with resistant hypertension, particularly in the elderly. These
include obstructive sleep apnea, renal parenchymal disease,
renal artery stenosis, and primary aldosteronism [28, 29]
(Table 1).
Obstructive sleep apnea is particularly frequent in
patients with resistant hypertension. A small study of 41
patients with resistant hypertension discovered that 83%
suﬀered from sleep apnea [30]. The severity of sleep apnea
is positively associated with the likelihood of resistant hy-
pertension [31, 32]. Several mechanisms are believed to con-
tribute to this eﬀect. Intermittent hypoxemia and increased
upper airway resistance induce a sustained increase in sym-
patheticnervoussystemactivity [33,34].Also,thereseems to
beasigniﬁcantly higherprevalenceofprimary aldosteronism
in patients with sleep apnea [35, 36]. Alternatively, obesity
may be the common factor that increases risk for both
obstructive sleep apnea and excess aldosterone production
[35]. A sleep study is indicated in patients with resistant
hypertension and other signs and symptoms of sleep apnea
including obesity, large neck size, excessive loud snoring,
interrupted sleep, daytime somnolence, polycythemia, and
carbondioxide retention[37, 38]. Treatment with a continu-
ous positive airway pressure device (CPAP) has been shown
to reduce blood pressure and thus is beneﬁcial in resistant
hypertension patients with obstructive sleep apnea [3].
The recent studies suggest that primary aldosteronism is
a much more common cause of hypertension than originally
believed. Particularly in patients with resistant hypertension,
the prevalence of primary aldosteronism has been found
between 10% and 20% [3, 39, 40]. Aldosterone exerts a
number of eﬀects leading to increased systemic vascular
resistance, such as endothelial dysfunction, vascular re-
modeling through collagen deposition, vascular damage,
impairment ofthebaroreﬂex leadingtolossofcompensation
for elevated blood pressure, and hypovolemia [41–43]. It has
been suggested that obesity is involved, causing a general-
ized activation of the renin-angiotensin-aldosterone system,
Table 1: Causes of resistant hypertension.
Exogenous substances
Drug related (see Table 2)
Herbal preparations (licorice, ephedra, ginseng, yohimbine, ma
huang, and bitter orange)
Alcohol consumption
Excess sodium intake
Concomitant conditions
Obesity
Insulin resistance
Smoking
Pseudoresistance
White-coat hypertension
Pseudohypertension in the elderly
Measurement artifact
Physician inertia
Secondary causes of hypertension
(i) Common causes
Renovascular disease
Renal parenchymal disease
Primary aldosteronism
Pheochromocytoma
Cushing syndrome
Thyroid and parathyroid disease
Coarctation of the aorta
(ii) Rare causes
Aneurysm located at the bifurcation of the right renal artery
Arterial thrombosis from abdominalaorta to both common
iliac arteries
Occlusion of the left renal artery
Hypercalcemia
Carcinoid syndrome
Central nervous system tumors
Premenstrual syndrome
perhaps through excretion of cytokines from adipocytes
[44, 45].
Primary aldosteronism maybe suggestedby hypokalemi-
a; however this is often a late manifestation preceded by the
development of hypertension [46–48]. Screening should be
done with plasma renin and serum aldosterone ratio mea-
surement (which has a high sensitivity but low speciﬁcity)
and conﬁrmed with sodium loading or ﬂudrocortisone sup-
pression testing [39, 49].
Renal parenchymal disease is both a cause and a com-
plication of poorly controlled hypertension [50, 51]. As
was previously mentioned, in ALLHAT serum creatinine
above 1.5mg/dL was the strongest predictor of failure to
achieve goal blood pressure [8]. Resistant hypertension
in chronic kidney disease is mainly due to activation of
the renin-angiotensin system, sodium retention, and the
resulting intravascular volume expansion [52]. Other factors
include activation of the sympathetic nervous system due to
decreased blood ﬂow to the kidney, alterations in vasocon-
strictor and vasodilator excretion from the endothelium,and
increased arterial stiﬀness [52].4 International Journal of Hypertension
Table 2: Drug related causes of resistant hypertension.
Drug-related causes
Nonadherence
Suboptimal medication regimen
Inappropriate combinations
Drug actions and interactions
(i) Drugs that regularly raise blood pressure:
Anabolic steroids
Sympathomimetic amines (midodrine)
Cocaine
Nicotine
(ii) Drugs that often raise blood pressure:
Ethanol (in excess)
Corticosteroids
Cyclosporin
Erythropoietin
Anorectics
NSAIDs including COX-2 inhibitors
Ergot alkaloids
(iii) Drugs that occasionallyraise blood pressure:
Caﬀeine
Phenothiazines
Tricyclics
Oral contraceptives
(iv) Drugs that cause hypertension on withdrawal:
Clonidine
B-blockers
(v) Drugs that cause hypertension by interaction:
MAOIs
Renal artery stenosis is a relatively common ﬁnding
in hypertensive patients undergoing cardiac catheterization
with approximately 20% of patients having unilateral or
bilateral stenosis above 70% [53]. However the causative
role of these stenosis in hypertension remains unknown
since only a few patients actually beneﬁt from surgical or
endovascular revascularization [54, 55]. The majority of
cases (90%) are due to atherosclerotic lesions and are seen in
older patients, smokers, patients with known atherosclerotic
disease and unexplained renal insuﬃciency [56]. The other
10% are ﬁbromuscular lesions, commonly in women under
50 years of age, and these are the patients that will usu-
ally improve blood pressure control after revascularization
[3]. Bilateral renal artery stenosis should be suspected in
patients with a history of “ﬂash” pulmonary edema with
preserved systolic heart function. Screening can be done
using magnetic resonance angiography (MRA), computer
tomographic angiography (CTA), Doppler ultrasonography,
or angiotensin converting enzyme (ACE) inhibitor renogra-
phy [49, 57].
Pheochromocytoma is a rare cause of resistant hyperten-
sion with a prevalence of 0.1%–0.6% among hypertensives
[58, 59]. The average time between initial symptoms and
diagnosis is 3 years, and many cases are missed altogether
according to autopsy studies [60]. Clinical signs include
episodic headaches, palpitations, and sweating. The best
screening test for pheochromocytoma is 24-hour urinary
Table 3: Resistant hypertension workup.
Identify and correct pseudoresistance
(i) Perform proper measurements of blood pressure.
(ii) Evaluate white coat hypertension with reliable home or
24-hour blood pressure measurements.
(iii) Evaluate patient adherence and improve it with education,
prescription of the least costly eﬀective drug regimen with the
fewest potential adverse eﬀects. Prefer once daily ﬁxed-dose
combination products.
Lifestyle modiﬁcations
(i) Ask the patient about use of any pharmacological/herbal
substances that may increase blood pressure.
(ii) Evaluate of the amount of alcohol intake.
(iii) Evaluate dietary salt intake and recommend sodium
restriction to <100mmol (2.4g) per day.
(iv) Assess the degree of obesity, abdominal obesity, and physical
activity and recommend weight reduction and regular aerobic
exercise (at least 30min/day, most days of the week).
Identify factors contributing to true resistance
(i) Evaluate renal function with estimation of glomerular
ﬁltration rate and modify treatment accordingly.
(ii) Search for causes of secondary hypertension
Tailor treatment according to patient characteristics using optimal doses of
appropriate medications. If all fails refer to hypertension specialist.
metanephrines or plasma free metanephrines (normeta-
nephrine and metanephrine) which carries a 99% sensitivity
and an 89% speciﬁcity [61].
Hypertension is a common manifestation of Cushing’s
syndrome. Up to 90% of patients are hypertensive and 17%
have resistant hypertension [62, 63]. The primary mech-
anism is increased mineralocorticoid activity that leads to
increased intravascular volume [64]. However, other factors
such as obstructive sleep apnea and insulin resistance also
contribute substantially [65, 66]. Target organ damage in
C u s h i n g ’ ss y n d r o m ei sm o r es e v e r et h a ni np r i m a r yh y p e r -
tension because it is associated with many other cardiovas-
cular risk factors such as diabetes, obstructive sleep apnea,
obesity, and dyslipidemia [67, 68].
Thyroid and parathyroid dysfunction are common re-
versible causes of secondary hypertension. Patients with hy-
perthyroidism usually present with systolic hypertension and
thosewithhypothyroidism havediastolichypertension.Most
patients with primary hyperparathyroidism are diagnosed
because of routine ﬁndings ofhypercalcemia [69, Table 1-2].
5.PharmacologicalTreatment
Pharmacological treatment should be based on the most
common causes of resistant hypertension and focused on
blocking all the physiological pathways to blood pressure
elevation [18, 70]. Antihypertensive agent doses should be
titrated upward until blood pressure is controlled or the
maximum recommended dosage is reached, unless the
patient experiences dose related adverse eﬀects. It is then
appropriate to add a drug from another class that has
additive or synergistic eﬀectswith the ﬁrst drug. In general, a
typical regimen should include a diuretic, an ACE inhibitorInternational Journal of Hypertension 5
or angiotensin receptor blocker (ARB), a calcium channel
blocker(CCB), and a β-blocker.
The timing of medication administration can also aﬀect
blood pressure control. Switching one of 3 or more medi-
cations from morning to bedtime administration can result
normalization of blood pressure in 21.7%–37% of patients
[71, 72]. This is particularly important in nondippers. Since
volume overload is the most frequent underlying patho-
physiology and suboptimal dosing the most frequent cause
of resistant hypertension, adding, increasing or changing
diuretic therapy is the key to successful treatment and will
help over 60% of patients achieve target blood pressure
[18, 73–77].
Patients with normal kidney function should receive
12.5–25mg/day of hydrochlorothiazide although some will
beneﬁt from doses up to 50mg/day [73]. Chlorthalidone at
25mg/day is an alternative that oﬀers greater 24-hour blood
pressure reductionthan 50mg/day hydrochlorothiazide with
the greatest diﬀerence occurring overnight and may be pre-
ferred in certain patients with resistant hypertension [78].
When given at the same dose as hydrochlorothiazide, chlor-
thalidone will reduce blood pressure an additional 8mmHg
according to a small study [79]. Patients should be mon-
itored for hyponatremia and hypokalemia, and caution is
warranted in patients with a history of prediabetes and
gout. A common pitfall is not realizing that the patient’s
kidney function is deteriorating and not switching diuretic
class when it does. Thiazide diuretics are not eﬀective in
chronic kidney disease. Therefore, they must be replaced
with loop diuretics when the estimated glomerular ﬁltration
rate (eGFR) falls below 40mL/min/1.73m2 [27, 73, 80]. In a
study of 12 elderly patients with hypertension whose blood
pressure was uncontrolled on multidrug regimens the use
of furosemide signiﬁcantly improved blood pressure control
[81]. Furosemide and bumetanide have a relatively short
half-life and should be dosed twice daily in order to avoid
reactive sodium retention due to intermittent natriuresis
and consequent activation of the renin-angiotensin system
[73, 80, 82].
When optimal diuresis fails, other medications should
be considered. Since subclinical aldosteronism is a common
occurrence in resistant hypertension, low doses of spirono-
lactone (25–50mg/day) or eplerenone can be particularly
helpful. Patients most expected to beneﬁt from mineralo-
corticoid blockade include those with primary hyperaldos-
teronism, the obese, and those suﬀering from obstructive
sleep apnea. Accordingto one study, the addition ofspirono-
lactone 12.5–25mg/day to 76 patients with uncontrolled
hypertension taking an average of 4 antihypertensive agents
resulted in an average25/12mmHg reduction after 6 months
[83]. The blood pressure lowering arm of the ASCOT study
had similar results for patients who were unselected for
aldosterone/plasma renin activity. When spironolactone was
added as a fourth line agent, blood pressure dropped by
21.9/9.5mmHg. At this dosage spironolactone is safe, well
tolerated and provides signiﬁcant additive blood pressure
reduction [84, 85]. Eplerenone may be more suitable for
patients requiring spironolactone doses above 25mg/day
because breast tenderness is a common adverse eﬀect at
higher doses [86]. Hyperkalemia is another risk that must be
monitored.
Amiloride is an alternative indirect aldosterone antago-
nist that is better tolerated than spironolactone. One small
study found that the addition of 2.5mg/day amiloride
decreased blood pressure by 31/15mmHg [40]. However, it
has been shown that 10mg of amiloride has half the blood
pressure reduction capability of 25mg spironolactone and
therefore should be considered only when spironolactone is
not tolerated [87].
Blockade of the renin angiotensin system with ACE in-
hibitors or ARBs in patients that are intolerant of ACE
inhibitors is particularly recommended in patients with
diabetes mellitus, heart failure, postmyocardial infarction,
chronic kidney disease, high coronary disease risk, and
recurrent stroke prevention [27, 88]. Dosage should be
increased to the maximum recommended dosage as long
serum creatinine does not increase more than 35% above
baseline and hyperkalemia does not develop [1–11]. Dual
ACE and ARB therapy is no longer recommended in most
cases because of the possibility of adverse renal outcomes
[89, 90].
Aliskiren, the only available direct renin inhibitor, is
at least as eﬀective as ARBs in reducing end target organ
damage but has not been directly tested in resistant hyper-
tension. The ALLAYtrial showed that aliskiren monotherapy
w a sa se ﬀective as losartan in reducing LVMI, although
the combination of both did not achieve a statistically
signiﬁcant further LVMI regression [91]. The addition of
aliskiren to losartan did however seem to have additional
renoprotective eﬀects in another study, reducing the mean
urinary albumin creatinine ratio by 20% in patients with
diabetic nephropathy [92]. The additional blood pressure
reduction was marginal and therefore the role of direct
rennin inhibitors in resistant hypertension remains undeter-
mined.
Polypharmacyisdiﬃculttoavoidbecausebloodpressure
can be controlled by using one drug in only about 50% of
patients. Fixed dose combinations oﬀer the convenience of
taking fewer pills, combining antihypertensive agents with
additive or synergistic eﬀect and reducing dose-dependant
adverse eﬀects of individual components. The latter is
evident in ACE inhibitor or ARB combinations with CCBs,
astheACEinhibitors/ARBsreducetheperipheraledemathat
frequently develops with dihydropyridine calcium channel
blocker therapy. Another popular ﬁxed dose combination
with synergistic eﬀects is ACE inhibitors/ARBs with diuret-
ics, since the latter enhance the antihypertensive eﬃcacy of
all the other classes. The recent introduction of triple agent
combinations containing dihydropyridine CCBs as well is
expected to lessen the burden of polypharmacy and further
improve adherence [86].
CCBs are particularly indicated in black and elderly
patients. The ACCOMPLISH study suggested that com-
bining ACE inhibitors with CCBs was more eﬀective at
preventing major cardiovascular and renal events than ACE
inhibitors with diuretics despite achieving similar blood
pressure control rates [93]. Both regimens are available as
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circumstances. In cases of true resistant hypertension, there
are also data to support adding a complementary non di-
hydropyridine CCB to a regimen including a RAS blocker,
diuretic, and dihydropyridine CCB. Such a combination of
complementary CCBs results in additive BP reduction with
al o w - s i d ee ﬀect proﬁle and makes pharmacological sense
[94, 95].
Beta-blockers are indicated in the setting of coronary
artery disease, congestive heart failure, and postmyocardial
infarction. When adding on combinations already including
a diuretic, an ACE inhibitor or ARB and a calcium channel
blocker,vasodilating β-blockersshould be preferred [73, 96].
Beta-blockers as well as loop diuretics are also usually nec-
essary when administering direct vasodilators to overcome
the reﬂex tachycardia and ﬂuid retention, respectively [97].
If BP control is still not achieved with full doses of a 4-drug
combination, use of other agents such as centrally acting
alpha-agonists (methyldopa and clonidine) or vasodilators
(hydralazine or minoxidil) is needed. These agents are very
eﬀective for lowering BP but have poor tolerability, require
frequent dosing, and lack positive outcome data [27]. At
this stage, the intervention of a hypertension specialist
is warranted. Besides these established treatments, new
antihypertensive agents are being developed.
Endothelin receptor antagonists are a new family of anti-
hypertensive medications that are currently being evaluated.
Darusentan is a selective antagonist for type A endothelin
receptors, activation of which causes vasoconstriction and
proliferation of vascular smooth muscle [98]. It has demon-
strated signiﬁcant dose-dependant reductions in both sys-
tolic and diastolic blood pressures and has been positively
evaluated in resistant hypertension [98, 99]. Unfortunately,
another unpublished phase 3 clinical trial failed to meet its
coprimaryend pointandthedrug’sfutureremains uncertain
[100]. Atrasentan is another highly selective endothelin
receptor antagonist that has shown positive results in blood
pressure reduction for 72 patients [101]. Interestingly, it
also had a positive inﬂuence on the patients metabolic
proﬁle. Another promising category under development
is medication that combines inhibitors of vasoconstrictive
mediators with drugs that potentiate vasodilating mediators
by inhibiting their breakdown by neutral endopeptidases
(NEPs). Omapatrilat is such an agentthat has beenevaluated
favorably in the OCTAVE trial [102]. Vaccines targeting
angiotensin I and II are also being developed and tested
[103, 104].
In any case, treatment should be tailored to the patient’s
proﬁle, lifestyle, and comorbidities. Constructing a regimen
that is acceptable to the patient, well tolerated and will
maintain long-term compliance is important. Yet in some
patients, optimal blood pressure control will not be achieved
evenwiththemostcarefullydesignedregimen.Inthesecases,
new device-based approaches for blood pressure control are
being evaluated (Tables 1 and 2).
One of these devices is the Rheos device (CVRx, Maple
Grove, Minn) which stimulates the carotid baroreceptors
for better blood pressure control by taking advantage of
chronicelectricalactivationoftheaﬀerentlimbofthecarotid
baroreﬂex. The device consists of a pulse generator and
bilateral perivascular carotid sinus leads that are implanted
under narcotic anesthesia. According to the ﬁndings from
the Device-Based Therapy of Hypertension (DEBuT-HT)
study that were recently presented, after four years of
treatment, Rheos reduced systolic blood pressure by an
average of 53mmHg (193mmHg versus 140mmHg). Blood
pressure was reduced signiﬁcantly each year, with the largest
decrease occurring in year four. Many of these patients
were able to reach their blood pressure goal and reduce the
number of medications that patients were taking to treat
their hypertension from an average of 5 at baseline to 3.4
medications at 4 years. Baroreﬂex activation therapy also
improved functional capacity and reduced left ventricular
mass without any evidence of carotid injury or stenosis
[105].
Another target for the interventional treatment of resis-
tant hypertension is catheter-based renal nerve ablation.
Renal sensory aﬀerent nerve activity directly inﬂuences sym-
pathetic outﬂow to the kidneys and other highly innervated
organs involved in cardiovascular control, such as the heart
and peripheral blood vessels, by modulating posterior hy-
pothalamic activity [106, 107]. All these components are
stimulated in hypertension and contribute to blood pressure
elevation.
Renal sympathetic nerve ablation is achieved percuta-
neously via the lumen of the renal artery, using a catheter
connected to a radiofrequency generator. Treatment has
been administered to 45 patients with resistant hypertension
takinga median of4.7antihypertensive agents.Followupat1
and 2 years has shown a sustained blood pressure reduction
of 27/11mmHg [108, 109]. The multicentre Simplicity
HTN-1 study that was recently presented at the European
SocietyofHypertension’s20thmeetingincluded108patients
with persistently elevated blood pressure despite treatment
with an average of ﬁve medications. Catheter-based renal
denervation produced a mean blood pressure reduction of
33/15mmHg at 24 months without evidence of vascular
or renal abnormalities. Results from the Simplicity HTN-
2 study comparing renal denervation treatment to rigorous
medical therapy are expected by the end of 2010.
6.Conclusions
Resistant hypertension remains a challenging clinical prob-
lem that will increasingly become more common. Causes of
resistance should be considered when blood pressure does
not respondsatisfactorily toarationaltripleantihypertensive
regimen that includes a diuretic. The workup of patients
with resistive hypertension should be a two-step approach
(Table 3): ﬁrst, conﬁrmation that it is indeed true resistant
hypertension by ruling out or correcting factors associated
with pseudoresistance, and second, identiﬁcation of the true
factors involved in treatment resistance. The cornerstone of
therapyremains arigorousevaluationfollowed bycorrection
of contributing causes and appropriate pharmacological
treatment. Newer interventional therapies may become a
viable option in the future for those patients with uncon-
trolled hypertension despite receiving an optimal multipleInternational Journal of Hypertension 7
medication antihypertensive regimen and those who cannot
tolerate the medication.
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